The future of biologic agents in the treatment of Sjögren's syndrome

Jiska M Meijer, Justin Pijpe, Hendrika Bootsma, Arjan Vissink, Cees G M Kallenberg

Research output: Contribution to journalReview articleAcademicpeer-review

32 Citations (Scopus)

Abstract

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN- alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

Original languageEnglish
Pages (from-to)292-7
Number of pages6
JournalClinical Reviews in Allergy & Immunology
Volume32
Issue number3
DOIs
Publication statusPublished - 11 Sept 2007
Externally publishedYes

Bibliographical note

Cop. Humana Press Inc. 2007

Fingerprint

Dive into the research topics of 'The future of biologic agents in the treatment of Sjögren's syndrome'. Together they form a unique fingerprint.

Cite this